PENNINGTON, N.J., March 12, 2025 /PRNewswire/ -- Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral...
Hence then, the article about zynext ventures invests in illexcor therapeutics to advance novel oral therapy for sickle cell disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease )
Also on site :
- EU open to reversing Brexit after Burnham speech – but at a price
- Six Flags Magic Mountain Permanently Closes World-Famous X2 Roller Coaster Following Mounting Safety Concerns
- Jimmy Fallon Just Dropped a Brutal Title for Karoline Leavitt’s Hypothetical Memoir, and the Internet Is Having a Field Day